Articles from Amplia Therapuetics Limited

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

HIGHLIGHTS

By Amplia Therapuetics Limited · Via GlobeNewswire · December 19, 2025

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

HIGHLIGHTS

By Amplia Therapuetics Limited · Via GlobeNewswire · December 12, 2025

Key Narmafotinib Patent Granted in the U.S.

Highlights

By Amplia Therapuetics Limited · Via GlobeNewswire · December 3, 2025